Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
Author:
Bourhill Tarryn,Mori Yoshinori,Rancourt Derrick,Shmulevitz Maya,Johnston Randal
Abstract
Oncolytic viruses show intriguing potential as cancer therapeutic agents. These viruses are capable of selectively targeting and killing cancerous cells while leaving healthy cells largely unaffected. The use of oncolytic viruses for cancer treatments in selected circumstances has recently been approved by the Food and Drug Administration (FDA) of the US and work is progressing on engineering viral vectors for enhanced selectivity, efficacy and safety. However, a better fundamental understanding of tumour and viral biology is essential for the continued advancement of the oncolytic field. This knowledge will not only help to engineer more potent and effective viruses but may also contribute to the identification of biomarkers that can determine which patients will benefit most from this treatment. A mechanistic understanding of the overlapping activity of viral and standard chemotherapeutics will enable the development of better combinational approaches to improve patient outcomes. In this review, we will examine each of the factors that contribute to productive viral infections in cancerous cells versus healthy cells. Special attention will be paid to reovirus as it is a well-studied virus and the only wild-type virus to have received orphan drug designation by the FDA. Although considerable insight into reoviral biology exists, there remain numerous deficiencies in our understanding of the factors regulating its successful oncolytic infection. Here we will discuss what is known to regulate infection as well as speculate about potential new mechanisms that may enhance successful replication. A joint appreciation of both tumour and viral biology will drive innovation for the next generation of reoviral mediated oncolytic therapy.
Funder
Canadian Institutes of Health Research
Canadian Breast Cancer Foundation
Subject
Virology,Infectious Diseases
Reference157 articles.
1. Remissions in leukemia of childhood following acute infectious disease. Staphylococcus and streptococcus, varicella, and feline panleukopenias
2. History of Oncolytic Viruses: Genesis to Genetic Engineering
3. FDA Approves Amgen’s Injected Immunotherapy for Melanomahttp://www.reuters.com/article/2015/10/27/us-amgen-fda-idUSKCN0SL2YH20151027
4. Announces Receipt of Orphan Drug Status from the Ema for Pancreatic Cancerhttp://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Announces-Receipt-of-Orphan-Drug-Status-from-the-EMA-for-Pancreatic-Cancer/default.aspx
5. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Gastric Cancerhttp://www.oncolyticsbiotech.com/news/press-release-details/2015/Oncolytics-Biotech-Inc-Announces-Receipt-of-Orphan-Drug-Designation-from-the-US-FDA-for-Gastric-Cancer/default.aspx
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献